Alternative-Site PREP Binding Ligands for Autophagy Induction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional PREP inhibitors fail to effectively modulate PREP function for disease-modifying drug therapy due to their binding to the active site, leading to inconclusive effects on neuropeptide levels and protein aggregation, particularly in neurodegenerative diseases like Parkinson's and Alzheimer's, and lack of autophagy induction.
Innovation Solution
Development of novel PREP binding ligands that bind to an alternative site outside the active site, modulating PREP function to enhance autophagy and PP2A activity, thereby reducing protein aggregation and oxidative stress.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional PREP inhibitors bind to the active site to inhibit PREP activity, then proteolytic activity is reduced, but the effect on neuropeptide levels and protein aggregation remains inconclusive and autophagy induction is not achieved
Solution Approach 1:
The patent introduces an alternative binding site as an intermediary location that mediates PREP modulation without requiring active site occupation. This alternative site serves as a mediator that triggers downstream effects (autophagy induction and PP2A activation) through a different mechanism than direct active site inhibition, thereby achieving the desired therapeutic effects that conventional inhibitors fail to produce.
Solution Approach 2:
The invention changes the binding location parameter from the active site to an alternative site on the PREP protein. This parameter change fundamentally alters the mechanism of action, transforming the inhibitor from a direct proteolytic blocker to a modulator that induces autophagy and activates PP2A, thereby achieving disease-modifying effects rather than merely reducing enzyme activity.
2Reliability
If PREP inhibitors are developed to restore neuropeptide levels in neurodegenerative diseases, then proteolytic cleavage is reduced, but the impact on memory and neuropeptide levels in vivo could not be confirmed
Solution Approach 1:
The patent converts the limitation of conventional inhibitors (inability to confirm in vivo effects) into a benefit by targeting a different mechanism. Instead of relying on proteolytic inhibition to restore neuropeptide levels, the invention uses alternative site binding to induce autophagy and activate PP2A, which indirectly but effectively clear protein aggregates and restore cellular function, achieving disease-modifying effects that were unattainable with active site inhibitors.
3Reliability
If PREP binding ligands are used to block alpha-synuclein aggregation, then protein aggregation is reduced, but the mechanism of action was unclear until the alternative binding site was identified
Solution Approach 1:
The patent segments the PREP protein into distinct functional regions: the active site and the alternative binding site. This segmentation reveals that the alternative site, located in a different region of the protein, is responsible for modulating PREP function to block alpha-synuclein aggregation, while the active site remains intact for its canonical proteolytic function. This spatial segmentation clarifies the mechanism of action.
Solution Approach 2:
The invention applies local quality by assigning different functional properties to different regions of the PREP protein. The alternative binding site possesses the specific quality of inducing autophagy and activating PP2A when bound by ligands, while the active site maintains its proteolytic function. This local differentiation explains how PREP can be modulated to block aggregation without requiring active site occupation.
Data Source
AI summary
The invention concerns a novel class of Prolyl oligopeptidase binding ligands, a pharmaceutical composition comprising same, the use of said ligands as medicaments, particularly, but not exclusively to promote autophagy and/or treat a disease involving a reduction in PPA2 activity or PP2A dysfunction.